0001768245-20-000002.txt : 20201204
0001768245-20-000002.hdr.sgml : 20201204
20201204140022
ACCESSION NUMBER: 0001768245-20-000002
CONFORMED SUBMISSION TYPE: D
PUBLIC DOCUMENT COUNT: 1
ITEM INFORMATION: 06b
FILED AS OF DATE: 20201204
DATE AS OF CHANGE: 20201204
EFFECTIVENESS DATE: 20201204
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: Viewpoint Molecular Targeting, Inc.
CENTRAL INDEX KEY: 0001768245
IRS NUMBER: 263526327
STATE OF INCORPORATION: DE
FILING VALUES:
FORM TYPE: D
SEC ACT: 1933 Act
SEC FILE NUMBER: 021-382294
FILM NUMBER: 201369539
BUSINESS ADDRESS:
STREET 1: 2500 CROSSPARK ROAD E-116
CITY: CORALVILLE
STATE: IA
ZIP: 52241
BUSINESS PHONE: 8653561861
MAIL ADDRESS:
STREET 1: 2500 CROSSPARK ROAD E-116
CITY: CORALVILLE
STATE: IA
ZIP: 52241
D
1
primary_doc.xml
X0708
D
LIVE
0001768245
Viewpoint Molecular Targeting, Inc.
2500 CROSSPARK ROAD E-116
CORALVILLE
IA
IOWA
52241
8653561861
DELAWARE
Viewpoint Molecular Targeting, LLC
None
Corporation
true
Frances
Johnson
2500 Crosspark Road E-116
Coralville
IA
IOWA
52241
Executive Officer
Director
Michael
Schultz
2500 Crosspark Road E-116
Coralville
IA
IOWA
52241
Executive Officer
Director
Heyward
Coleman
2500 Crosspark Road E-116
Coralville
IA
IOWA
52241
Executive Officer
Director
Curtis
Nelson
2500 Crosspark Road E-116
Coralville
IA
IOWA
52241
Director
Cameron
Gray
1221 Shafter Street
San Mateo
CA
CALIFORNIA
94402
Director
Biotechnology
Decline to Disclose
- 06b
false
2020-11-20
false
true
false
25000
National Securities Corporation
7569
None
None
5000 T-Rex Avenue
Suite 300
Boca Raton
FL
FLORIDA
33431
CA
CALIFORNIA
DC
DISTRICT OF COLUMBIA
FL
FLORIDA
IL
ILLINOIS
IA
IOWA
MD
MARYLAND
NE
NEBRASKA
SC
SOUTH CAROLINA
TX
TEXAS
false
15847498
8843739
7003759
Total offering amount is subject to increase by the issuer. Total offering amount and total amount sold include conversion of outstanding debt in the aggregate amount of $847,498.
false
26
600056
0
Cash sales compensation of $550,056.25 and reimbursed expenses of $50,000. Additionally, warrants to purchase 584,751 shares of common stock of the issuer at the per share offering price were issued to the broker.
500000
true
Compensation to executive officers in the ordinary course pursuant to their Board-approved existing employment agreements.
false
Viewpoint Molecular Targeting, Inc.
Frances Johnson
Frances Johnson
CEO
2020-12-04